Polycystic ovary syndrome in adolescents suffering from excessive body weight and insulin resistance


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Objective. Evaluate the features of phenotypic variants of PCOS during adolescence with regard to body mass index and insulin resistance (IR). Materials and methods. A study in parallel groups was conducted. The total of 95 girls with PCOS from 15 to 17 years old were divided into four groups according to the presence or absence of IR and excessive body weight. The control group consisted only of lean healthy girls without IR with regular menstrual cycle. All participants underwent full clinical and instrumental examination, assessment of the level of С-reactive protein, leptin. Results. The obese insulin resistant PCOS group in comparison with lean nonIR PCOS group was characterized with the most unfavorable atherogenic lipid prof ile and biochemical hyperandrogenism due to the decreased level of sex hormone binding protein (SHBP), more pronounced pro-inflammatory activation according to higher levels of CRP (p = 0.0011), leptin (p= 0.0004) and white blood cell count (p=0.0235), platelets (p = ft. 0012), neutrophils (p = 0.0440) and ESR (p = 0.0036). The obese insulin resistant PCOS group compared with the control group characterized not only by significantly higher values of HOMA-IR (p = 0.0026), fasting glucose (p = 0.0021), higher TG levels (p = 0.0237), atherogenic coefficient (p = 0.0010) and cardiovascular risk by the VAI index (p = ft. 0105), lower HDL content (p = ft. 0459), and higher value of CRP (p = ft. 0239) and leptin (p = 0.0034) levels. Lean PCOS insulin resistant group significantly differed from lean nonIR PCOS group with a higher iron content (p = 0.0423), higher TG (p = ft. 0056) and atherogenic coefficient values (p = ft. 0262), lower levels of HDL (p = 0.0391), which proved dyslipidemia, despite the normative В ML in this group. Lean PCOS insulin resistant group differed significantly from the control group with higher levels of total and direct bilirubin (p = 0.0076 and p = 0.0155, respectively) and iron (23.8 ± 8.0 versus 16.6 ± 6, 8, p = 0.0343), and higher atherogenic coefficient values (p = 0.0206). Obese PCOS nonLR group differed from lean PCOS nonLR group with higher levels of CRP (p = 0.0226) and leptin (p = 0.0267), which indicates thatproinflammatory activation occurs in PCOS patients with excessive weight already in adolescence even in the absence of metabolic disorders. Lean PCOS nonLR group differed from the control group with a higher content of total protein (p = 0.0431) and direct bilirubin (p = ft. 0251). Conclusions: the combination of excessive body weight and metabolic disorders since adolescence is associated with increasing dyslipidemia and atherosclerosis, proinflammatory activation as well as an unfavorable cardiovascular risk.

Full Text

Restricted Access

About the authors

Elena P. Khashchenko

FSBI "National Medical Research Center for Obstetrics, Gynecology and Perinatology "of the Ministry of Healthcare of the Russian Federation

Email: khashchenko_elena@mail.ru
PhD, researcher at the Department of Pediatric Gynecology

Mikhail Yu. Vysokikh

FSBI "National Medical Research Center for Obstetrics, Gynecology and Perinatology "of the Ministry of Healthcare of the Russian Federation; A.N. Belozersky Research Institute of Physicochemical Biology

Email: m_vysokikh@oparina4.ru
PhD, Head of mitochondrial medicine research group; Head of aging molecular mechanism group

Zalina K. Batyrova

FSBI "National Medical Research Center for Obstetrics, Gynecology and Perinatology "of the Ministry of Healthcare of the Russian Federation

Email: linadoctor@mail.ru
PhD, researcher at the Department of Pediatric Gynecology

Zaira K. Kumykova

FSBI "National Medical Research Center for Obstetrics, Gynecology and Perinatology "of the Ministry of Healthcare of the Russian Federation

Email: zai-kumykova@yandex.ru
PhD, senior researcher at the Department of Pediatric Gynecology

Elena V. Uvarova

FSBI "National Medical Research Center for Obstetrics, Gynecology and Perinatology "of the Ministry of Healthcare of the Russian Federation

Email: elena-uvarova@yandex.ru
MD, PhD, Professor, Head of the Department of pediatric and adolescent gynecology

Tatyana Yu. Ivanetc

FSBI "National Medical Research Center for Obstetrics, Gynecology and Perinatology "of the Ministry of Healthcare of the Russian Federation

Email: t_ivanets@oparina4.ru
PhD, MD, Head of the Department of Research and Diagnostics Laboratory

Darya V. Tsvirkun

FSBI "National Medical Research Center for Obstetrics, Gynecology and Perinatology "of the Ministry of Healthcare of the Russian Federation

Email: darunyat@gmail.com
PhD, researcher at mitochondrial medicine research group

Valentina V. Vtorushina

FSBI "National Medical Research Center for Obstetrics, Gynecology and Perinatology "of the Ministry of Healthcare of the Russian Federation

Email: v_vtorushina@oparina4.ru
PhD, clinician of laboratory diagnostics at the department of clinical immunology

References

  1. Deligeoroglou E., Vrachnis N., Athanasopoulos N., Iliodromiti Z., Sifakis S., Iliodromiti S. et al. Mediators of chronic inflammation in polycystic ovarian syndrome. Gynecol. Endocrinol. 2012; 28(12): 974-8. doi: 10.3109/09513590.2012.683082.
  2. Чернуха Г.E., Блинова И.В., Купрашвили М.И. Эндокринно-метаболические характеристики больных с различными фенотипами синдрома поликистозных яичников. Акушерство и гинекология. 2011; 2: 70-6.
  3. El Hayek S., Bitar L., Hamdar L.H., Mirzfl E.G., Daoud G. Poly cystic ovarian syndrome: an updated overview. Front. Physiol. 2016; 7: 124. doi: 10.3389/ fphys.2016.00124.
  4. Rojas J., Chavez М., Olivar L., Rojas М., Morillo J., Mejias J. Polycystic ovary syndrome, insulin resistance, and obesity: navigating the patophysiologic labyrinth. Int. J. Reprod. Med. 2014; 2014: 719050. doi: 10.1155/2014/719050.
  5. De Sousa S.М., Norman R.J. Metabolic syndrome, diet and exercise. Best Pract. Res. Clin. Obstet. Gynaecol. 2016; 37: 140-51. doi: 10.1016/j.bpobgyn.2016.01.006.
  6. Goodman N.F., Cobin R.H., Eutterweit W., Glueck J.S., Legro R.S., Carmina E. American association of clinical endocrinologists, american college of endocrinology, and androgen excess and pcos society disease state clinical review: guide to the best practices in the evaluation and treatment of polycystic ovary syndrome- part 1. Endocr. Pract. 2015; 21(11): 1291-300. doi: 10.4158/EP15748.DSC.
  7. Oleszczak B., Szflblewski L., Pliszka М., Gluszak O., Stopinska-Gluszak U. Transport of deoxy-d-glucose into lymphocytes of patients with polycystic ovary syndrome. Endocrine. 2014; 47(2): 618-24. doi: 10.1007/sl2020-014-0174-5.
  8. Dumesic D.A., Oberfield S.E., Stener-Victorin E., Marshall J.C., Laven J.S., Legro R.S. Scientific statement on the diagnostic criteria, epidemiology, pathophysiology, and molecular genetics of polycystic ovary syndrome. Endocr. Rev. 2015; 36(5): 487-525. doi: 10.1210/er.2015-1018.
  9. Diamanti-Kandarakis E., Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr. Rev. 2012; 33(6): 981-1030.
  10. Gonzfllez E. Inflammation in polycystic ovary syndrome: underpinning of insulin resistance and ovarian dysfunction. Steroids. 2012; 77(4): 300-5. doi: 10.1016/j.steroids.2011.12.003.
  11. Yang Y., Qiao J., Li R., Li M.Z. Is interleukin-18 associated with polycystic ovary syndrome? Reprod. Biol. Endocrinol. 2011; 9: 7-18. doi: 10.1186/1477-7827-9-7.
  12. Tao Т., Li S., Zhao A., Zhang Y., Liu W. Expression of the CDllc gene in subcutaneous adipose tissue is associated with cytokine level and insulin resistance in women with polycystic ovary syndrome. Eur. J. Endocrinol. 2012; 167(5): 705-13. doi: 10.1530/EJE-12-0340.
  13. Escobar-Morreale H.F., Luque-Ramirez М., Gonzfllez, F. Circulating inflammatory markers in polycystic ovary syndrome: a systematic review and meta-analysis. Fertil. Steril. 2011; 95(3): 1048-58. doi: 10.1016/j.fertnstert.2010.11.036.
  14. Lee H., Oh J.Y., Sung Y.A. Adipokines, insulin-like growth factor binding protein-3 levels, and insulin sensitivity in women with polycystic ovary syndrome. Korean J. Intern. Med. 2013; 28(4): 456-63. doi: 10.3904/kjim.2013.28.4.456.
  15. Conway G., Dewailly D., Diamanti-Kandarakis E., Escobar-Morreale H.F., Franks S., Gambineri A. et al. The polycystic ovary syndrome: a position statement from the European Society of Endocrinology. Eur. J. Endocrinol. 2014; 171: 1-29. doi: 10.1530/EJE-14-0253.
  16. Amato М. C. Metabolically healthy polycystic ovary syndrome (MH-PCOS) and metabolically unhealthy polycystic ovary syndrome (MU-PCOS): a comparative analysis of four simple methods useful for metabolic assessment. Hum. Reprod. 2013; 28(7): 1919-28.

Supplementary files

Supplementary Files
Action
1. JATS XML

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies